Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06353217
Other study ID # IRB00419034
Secondary ID K23DK128572
Status Recruiting
Phase N/A
First received
Last updated
Start date April 14, 2024
Est. completion date April 14, 2026

Study information

Verified date April 2024
Source Johns Hopkins University
Contact Scott J Pilla, MD, MHS
Phone 9087680002
Email spilla1@jhmi.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single site, pre-post pilot study. The objective is to evaluate the acceptability and feasibility of a primary care hypoglycemia prevention program for patients taking hypoglycemia-causing medications. The study will also evaluate relevant process outcomes and clinical outcomes for refining the intervention and planning for a larger efficacy trial.


Recruitment information / eligibility

Status Recruiting
Enrollment 35
Est. completion date April 14, 2026
Est. primary completion date April 14, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria for patients: - Age 18 years or older - Diabetes mellitus by electronic health record review - Treatment with any of the following medication classes: insulin, sulfonylureas, meglitinides - Community dwelling (not residing in long-term care or a skilled nursing facility) - Receiving primary care from a participating primary care provider at Johns Hopkins Internal Medicine at Green Spring Station - The patient's primary care provider approves their participation Exclusion criteria for patients: - Significant cognitive impairment or dementia - Receiving hospice or end of life care - Any other serious illness or condition not compatible with participation as determined by the investigators - Planning to leave area prior to end of study - Investigator discretion Exclusion Criteria for continuous glucose monitoring (not required for study participation): - History of allergic skin reaction to adhesive - Implantable pacemaker Inclusion criteria for primary care providers: - Practicing at Johns Hopkins Internal Medicine Green Spring Station Exclusion criteria for primary care providers: - Planning to leave their position prior to end of study - Not serving as primary care provider for any included patient Inclusion criteria for clinic staff: - Participating in check-in at Johns Hopkins Internal Medicine Green Spring Station Exclusion criteria for clinic staff - Planning to leave their position prior to end of study

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Patient Group (Hypoglycemia Prevention Program)
The Hypoglycemia Prevention Program: The patient hypoglycemia profile - this is a set of survey questions about hypoglycemia and related aspects of diabetes care. The questions will be administered as an Epic MyChart message sent to the patient in the week prior to the clinic visit, and in the clinic waiting room on a tablet immediately prior to the patient's primary care provider visit.
Primary Care Physician Group
The provider hypoglycemia toolkit - this is the report from the patient hypoglycemia profile, which triggers a set of hypoglycemia prevention tools and patient education materials as appropriate. Primary Care Providers will not be exposed to the intervention until all of their patients have completed the Baseline Clinic Visit.
Clinic Staff Group
Clinic staff will provide the tablet to the participant immediately prior to the patient's primary care provider visit.

Locations

Country Name City State
United States Johns Hopkins University School of Medicine Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins University National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Intervention coherence (patients) Mean score for intervention coherence on patient intervention evaluation survey (developed for this study, range 1-strongly disagree, to 5-strongly agree) Immediately after the intervention
Other Opportunity costs (patients) Mean score for opportunity costs on patient intervention evaluation survey (developed for this study, range 1-strongly disagree, to 5-strongly agree) Immediately after the intervention
Other Ethicality (patients) Mean score for ethicality on patient intervention evaluation survey (developed for this study, range 1-very unfair, to 5-very fair) Immediately after the intervention
Other Affective attitude (patients) Mean score for affective attitude on patient intervention evaluation survey (developed for this study, range 1-very uncomfortable, to 5-very comfortable) Immediately after the intervention
Other Burden (patients) Mean score for burden on patient intervention evaluation survey (developed for this study, range 1-no effort at all, to 5-huge effort) Immediately after the intervention
Other Self-efficacy (patients) Mean score for self-efficacy on patient intervention evaluation survey (developed for this study, range 1-very un-confident, to 5-very confident) Immediately after the intervention
Other Perceived effectiveness (primary care providers) Mean score for perceived effectiveness on primary care provider intervention evaluation survey (developed for this study, range 1-strongly disagree, to 5-strongly agree) Immediately after the intervention
Other Intervention coherence (primary care providers) Mean score for intervention coherence on primary care provider intervention evaluation survey (developed for this study, range 1-strongly disagree, to 5-strongly agree) Immediately after the intervention
Other Opportunity costs (primary care providers) Mean score for opportunity costs on primary care provider intervention evaluation survey (developed for this study, range 1-strongly disagree, to 5-strongly agree) Immediately after the intervention
Other Affective attitude (primary care providers) Mean score for affective attitude on primary care provider intervention evaluation survey (developed for this study, range 1-very uncomfortable, to 5-very comfortable) Immediately after the intervention
Other Burden (primary care providers) Mean score for burden on primary care provider intervention evaluation survey (developed for this study, range 1-no effort at all, to 5-huge effort) Immediately after the intervention
Other Self-efficacy (primary care providers) Mean score for self-efficacy on primary care provider intervention evaluation survey (developed for this study, range 1-Very unconfident, to 5-very confident) Immediately after the intervention
Other Burden (clinic staff) Mean score for burden on clinic staff intervention evaluation survey (developed for this study, range 1-no effort at all, to 5-huge effort) Immediately after the intervention
Other Opportunity costs (clinic staff) Mean score for opportunity costs on clinic staff intervention evaluation survey (developed for this study, range 1-strongly disagree, to 5-strongly agree) Immediately after the intervention
Other Recruitment rate % of eligible participants who consented to participate Immediately after the intervention
Other Retention rate for second clinic visit % of participants who completed two clinic visits Immediately after the intervention
Other Continuous glucose monitoring (CGM) completion % of participants who completed CGM measurements Immediately after the final CGM measurement (4-12 weeks after the intervention)
Other Continuous glucose monitoring (CGM) wear time Mean days with complete CGM data Immediately after the final CGM measurement (4-12 weeks after the intervention)
Other Time needed to complete patient hypoglycemia profile Mean completion time (minutes) for patient hypoglycemia profile Immediately after completion of intervention clinic visit
Other Duration of clinical visit Change from baseline in mean duration of clinic visit (minutes) Change from baseline to immediately after completion of intervention clinic visit
Other Patient completion of hypoglycemia assessment Completion rate overall and for individual items Immediately after completion of intervention clinic visit
Other Primary care provider use of provider hypoglycemia toolkit Rate of toolkit use overall and for individual tools Immediately after completion of intervention clinic visit
Other Patient hypoglycemia burden on continuous glucose monitoring (CGM) Change from baseline in mean minutes per day with glucose <70 mg/dl and <54 mg/dl Baseline to post-intervention up to 12 weeks
Other Patient time below range on continuous glucose monitoring (CGM) Change from baseline in % time with glucose <70 mg/dl Baseline to post-intervention up to 12 weeks
Other Patient time above range on continuous glucose monitoring (CGM) Change from baseline in % time with glucose >180 mg/dl Baseline to post-intervention up to 12 weeks
Other Patient mean glucose on continuous glucose monitoring (CGM) Change from baseline in mean glucose Baseline to post-intervention up to 12 weeks
Other Patient satisfaction with care Change from baseline in mean score on The Patient Satisfaction Questionnaire Short Form (PSQ-18), range 1 (lowest satisfaction) to 5 (highest satisfaction) in 7 domains Change from baseline to immediately after the intervention
Other Patient activation Change from baseline in mean score on Patient Activation Measure (PAM 10), range 0 (lowest activation) to 100 (highest activation) Change from baseline to immediately after the intervention
Other Patient self-reported hypoglycemic events Change from baseline in frequency of level 1, level 2, and level 3 hypoglycemia events on hypoglycemia history survey Change from baseline to 4-12 weeks after the intervention
Other Changes to hypoglycemia-causing medications % of patients with changes in diabetes medications (dose increase, decrease, stop, switch, initiate) Change from baseline to immediately after the intervention
Other Glucagon prescription % of patients with active glucagon prescription Change from baseline to immediately after the intervention
Other Continuous glucose monitoring (CGM) prescription Change from baseline in frequency of CGM prescription Change from baseline to immediately after the intervention
Other Change in Frequency of Referrals to Diabetes Self Management Training (DSMT) Change from baseline in frequency of DSMT referral Change from baseline to immediately after the intervention
Other Frequency of hypoglycemia history discussions Frequency and content of hypoglycemia history discussion by audio-recording Change from baseline to immediately after the intervention
Other Frequency of Hypoglycemia anticipatory guidance discussions Frequency, content, and accuracy of hypoglycemia anticipatory guidance Change from baseline to immediately after the intervention
Other Frequency of Medication adherence discussions Frequency and content of discussions of adherence to diabetes medications Change from baseline to immediately after the intervention
Primary Overall acceptability to patients Mean score for overall acceptability on patient intervention evaluation survey (developed for this study, range 1-completely unacceptable, to 5-completely acceptable) Immediately after the intervention
Primary Overall acceptability to primary care providers Mean score for overall acceptability on primary care provider intervention evaluation survey (developed for this study, range 1-completely unacceptable, to 5-completely acceptable) Immediately after the intervention
Primary Overall acceptability to clinic staff Mean score for overall acceptability on clinic staff intervention evaluation survey (developed for this study, range 1-completely unacceptable, to 5-completely acceptable) Immediately after the intervention
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A